G. Vehar

发表

Characterization of the human factor VIII gene

E. Chen, D. Eaton, W. Wood, 1984, Nature.

Structure of human factor VIII

B. Keyt, H. Oppermann, W. Wood, 1984, Nature.

Circulatory metabolism of recombinant tissue-type plasminogen activator in monkeys and rabbits

B. Keyt, T. Bringman, G. Vehar, 1988 .

Gene expression profiling in an in vitro model of angiogenesis.

F. Peale, M. Gerritsen, D. Lewin, 2000, The American journal of pathology.

Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity.

G. Vehar, D. Eaton, H. Rodriguez, 1986, Biochemistry.

The cytoplasmic domain of tissue factor is phosphorylated by a protein kinase C-dependent mechanism.

S. Roy, G. Vehar, T. Zioncheck, 1992, The Journal of biological chemistry.

Characterization of recombinant human factor VIII.

P. Hass, M. Wiebe, G. Vehar, 1987, The Journal of biological chemistry.

Preparation and properties of bovine factor VIII (antihemophilic factor).

E. Davie, G. Vehar, 1980, Biochemistry.

Cloning and expression of the cDNA for human antithrombin mI

R. Lawn, K. Wion, G. Vehar, 2022 .

Strategies for manipulating apoptosis for cancer therapy with tumor necrosis factor and lymphotoxin

G. Wong, G. Vehar, G. Zweiger, 1996, Journal of cellular biochemistry.

Tumor necrosis factor and lymphotoxin: protection against oxidative stress through induction of MnSOD.

G. Wong, G. Vehar, R. Kaspar, 1996, EXS.

Structure of human factor VIII. Nature

B. Keyt, H. Oppermann, W. Wood, 1984 .

Cloning and expression of the cDNA for human antithrom, bin III

R. Lawn, G. Vehar, S. C. Bock, 1982 .

Mammalian cell transient expression of tissue factor for the production of antigen.

R. Lawn, G. Vehar, B. Fendly, 1990, Protein engineering.

Lysine residues 165 and 166 are essential for the cofactor function of tissue factor.

P. Hass, S. Roy, W. Henzel, 1991, The Journal of biological chemistry.

SPECIFIC BINDING OF l-0-ALKYL-Z-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE (PLATELET-ACTIVA TINE FACTOR) TO THE V~TACT CANINE PLATELET

G. Vehar, D. Janero, C. Burghardt, 1988 .

Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice

S. Bunting, S. Fong, B. Carter, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Levels of Human FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice Following Gene Therapy with BMN 270

Carter, S. Bunting, S. Fong, 2017 .

Production of Recombinant Coagulation Proteins

G. Vehar, 1987, Annals of the New York Academy of Sciences.

Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis.

Deborah L. Higgins, H. Heyneker, G. Vehar, 1987, Biochemistry.

The binding of factor IXa to cultured bovine aortic endothelial cells. Induction of a specific site in the presence of factors VIII and X.

W. Kisiel, D. Stern, P. Nawroth, 1985, The Journal of biological chemistry.

Functional arginine residues involved in coenzyme binding by dihydrofolate reductase.

G. Vehar, J. Freisheim, 1976, Biochemical and biophysical research communications.

What is the Prospective Impact of the Recombinant DNA Technique on the Production of Human Plasma Derivatives? Which Are the Derivates Where Donor Plasma Could be Replaced?

G. Vehar, L. Aledort, H. Pannekoek, 1983, Vox sanguinis.

Reaction of dihydrofolate reductase with dansyl chloride. Chemical modification of a sensitive lysine residue and fluorometric studies of the dansylated enzyme.

A. Reddy, G. Vehar, J. Freisheim, 1976, Biochemistry.

The molecular genetics of hemophilia.

R. Lawn, G. Vehar, 1986, Scientific American.

Expression of active human factor VIII from recombinant DNA clones

B. Keyt, P. Seeburg, E. Delwart, 1984, Nature.

Characterization Studies on Human Melanoma Cell Tissue Plasminogen Activator

W. Kohr, D. Pennica, G. Vehar, 1984, Bio/Technology.

Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli

P. Seeburg, W. Kohr, H. Heyneker, 1983, Nature.

Purification and Characterization of Recombinant Urokinase from Escherichia coli

W. Holmes, M. Blaber, G. Vehar, 1985, Bio/Technology.

Cloning and expression of human tissue factor cDNA.

R. Lawn, G. Vehar, C. Gorman, 1987, Thrombosis research.

Factor VIII-bypassing activity of bovine tissue factor using the canine hemophilic model.

A. Giles, G. Vehar, K. Tate, 1988, The Journal of clinical investigation.

Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule.

P. Hass, D. Eaton, W. Wood, 1986, Biochemistry.

Protein products from yeast.

W. Kohr, D. Dowbenko, V. Chisholm, 1988, Biochemical Society Transactions.

Formation of a serine enzyme in the presence of bovine factor VIII (antihemophilic factor) and thrombin.

E. Davie, G. Vehar, 1977, Science.

Characterization studies of human tissue-type plasminogen activator produced by recombinant DNA technology.

S E Builder, W S Hancock, W. Hancock, 1986, Cold Spring Harbor symposia on quantitative biology.

Interaction of one-chain and two-chain tissue plasminogen activator with intact and plasmin-degraded fibrin.

G. Vehar, D. Higgins, 1987, Biochemistry.

Self-association of tissue factor as revealed by chemical crosslinking.

S. Roy, G. Vehar, L. Paborsky, 1991, The Journal of biological chemistry.

Cloning and expression of the cDNA for human antithrombin III.

R. Lawn, K. Wion, G. Vehar, 1982, Nucleic acids research.

The Human Factor Viii Protein

G. Vehar, D. Eaton, 1985 .

Factor VIII structure and proteolytic processing.

G. Vehar, D. Eaton, 1986, Progress in hemostasis and thrombosis.

Bioengineering of blood plasma proteins.

G. Vehar, 2009, Scandinavian journal of haematology. Supplementum.